Last edition
News about "Schizophrenia treatment"
TG Therapeutics Launches Phase 2 Trial of BRIUMVI for Schizophrenia
TG Therapeutics has initiated a Phase 2 trial of BRIUMVI in treatment-resistant schizophrenia, evaluating B-cell depletion as a potential therapy for patients with immune dysfunction.
Schizophrenia Treatment | 07/07/2026 | By News Bureau
Newron Provides Update Following Type A Meeting with the US FDA
Newron has provided an update following its Type A meeting with the US Food and Drug Administration (FDA), outlining the steps required to resume US enrollment in the phase 3 ENIGMA-TRS 2 schizophrenia study.
Schizophrenia Treatment | 04/07/2026 | By News Bureau | 107
Saptalis Launches Cyclosporine Ophthalmic Emulsion
Saptalis Pharmaceuticals has launched Cyclosporine Ophthalmic Emulsion 0.05 percent in 30- and 60-count single-use vials, expanding its ophthalmology portfolio and improving access to high-quality treatment options for patients.
Schizophrenia Treatment | 16/06/2026 | By News Bureau
US FDA Approves CAPLYTA (lumateperone) sNDA for Schizophrenia Relapse Reduction
US Food and Drug Administration (FDA) approves CAPLYTA (lumateperone) sNDA for schizophrenia, showing a 63 percent reduction in relapse risk and 84 percent relapse-free patients over six months, with strong long-term safety and stability data.
Schizophrenia Treatment | 28/04/2026 | By News Bureau | 139
LB Pharmaceuticals Starts Phase 3 Trial for LB-102 in Schizophrenia
LB Pharmaceuticals initiates Phase 3 NOVA-2 trial of LB-102 for schizophrenia, enrolling ~460 patients to assess PANSS score, symptoms and safety, with topline results expected in 2H 2027.
Schizophrenia Treatment | 26/03/2026 | By News Bureau | 209
BYSANTI (milsaperidone), a new atypical antipsychotic from Vanda Pharmaceuticals, gains FDA approval for acute manic or mixed episodes in bipolar I disorder and schizophrenia in adults, with US launch planned for Q3 2026.
Schizophrenia Treatment | 21/02/2026 | By News Bureau | 310
Newron Pharmaceuticals Secures Euro 38 Million to Advance Phase III Schizophrenia Programme
Newron Pharmaceuticals strengthens its funding base with a multi-tranche equity raise to support late-stage development of evenamide in treatment-resistant schizophrenia.
Schizophrenia Treatment | 17/02/2026 | By News Bureau | 156
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy